Genetics: Animal and Human Cytochrome P450 Polymorphisms
- 380 Downloads
There is now considerable evidence for wide interindividual variation in cytochrome P450 activity in both humans and animals. This variation may be due to a genetic polymorphism which results in either lack of protein synthesis or synthesis of a protein with reduced enzyme activity or to variation in the level of cytochrome P450 gene expression due to regulation by factors such as hormones or xenobiotics. In this chapter, the effect of polymorphisms in cytochrome P450 genes on enzyme activity in the microsomal drug-metabolising cytochrome P450 families 1 to 3 will be considered.
KeywordsPoor Metabolisers Restriction Fragment Length Polymorphism Analysis Dark Agouti Cytochrome P450 Gene Human Liver Cytochrome
Unable to display preview. Download preview PDF.
- Distelrath LM, Reilly PEB, Martin MV, Davis GG, Wilkinson GR, Guengerich FP (1985) Purification and characterisation of the human liver cytochromes P450 involved in debrisoquine 4-hydroxylation and phenacetin O-deethylation, two prototypes for genetic polymorphism in oxidative drug metabolism. J Biol Chem 260: 9057–9067Google Scholar
- Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ (1979) Defective N-oxidation of sparteine in man: a new pharmacogenetic defect. Eur J Clin Pharmacol 17: 153–155Google Scholar
- Fonne-Pfister R, Bargetzi MJ, Meyer UA (1987) MPTP, the neurotoxin inducing Parkinson’s disease, is a potent competitive inhibitor of human and rat cytochrome P450 isozymes (P450bufl, P450dbl) catalysing debrisoquine 4-hydroxylation. Biochem Biophys Res Commun 148: 1144–1150PubMedCrossRefGoogle Scholar
- Gonzalez FJ, Matsunaga T, Nagata K, Meyer UA, Nebert DW, Pastewka J, Kozak CA, Gillette J, Gelboin HV, Hardwick JP (1987) Debrisoquine 4-hydroxylase: characterisation of a new P450 gene subfamily, regulation, chromosomal mapping and molecular analysis of the DA rat polymorphism. DNA 6: 149–161PubMedCrossRefGoogle Scholar
- Küpfer A, Dick B, Preisig R (1982) A new drug hydroxylation polymorphism in man: the incidence of mephenytoin hydroxylation deficient phenotypes in an European population study. Naunyn Schmiedebergs Arch Pharmacol 321: 33Google Scholar
- Larrey D, Distelrath LM, Dannan GA, Wilkinson G, Guengerich FP (1984) Purification and characterisation of the rat liver microsomal cytochrome P450 involved in the 4-hydroxylation of debrisoquine, a prototype for genetic variation in oxidative drug metabolism. Biochemistry 23: 2787–2795PubMedCrossRefGoogle Scholar
- Meehan RR, Gosden JR, Rout D, Hastie ND, Friedberg T, Adesnik M, Buckland R, van Heyningen V, Fletcher J, Spurr NK, Sweeney J, Wolf CR (1988) Human cytochrome P450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 42: 26–37PubMedGoogle Scholar
- Shimada T, Misono KS, Guengerich FP (1986) Human liver microsomal cytochrome P450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. J Biol Chem 261: 900–921Google Scholar
- Yasumori T, Kawano S, Nagata K, Shimada M, Yamazoe Y, Kato R (1987) Nucleotide sequence of a human liver cytochrome P450 related to the rat male-specific form. J Biochem (Tokyo) 102: 493–501Google Scholar